RnRMarketResearch.com offers “Bone Metastasis – Pipeline Review, H1 2015”global research report on its store.
This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report is available at http://www.rnrmarketresearch.com/bone-metastasis-pipeline-review-h1-2015-market-report.html .
Scope of The Report:
- The report provides a snapshot of the global therapeutic landscape of Bone Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bone Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to Buy This Report:
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bone Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=356479 .
Table of Content for “Bone Metastasis – Pipeline Review, H1 2015” research report includes:
Bone Metastasis Overview 9
Therapeutics Development 10
Pipeline Products for Bone Metastasis - Overview 10
Pipeline Products for Bone Metastasis - Comparative Analysis 11
Bone Metastasis - Therapeutics under Development by Companies 12
Bone Metastasis - Therapeutics under Investigation by Universities/Institutes 14
Bone Metastasis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Bone Metastasis - Products under Development by Companies 18
Bone Metastasis - Products under Investigation by Universities/Institutes 20
Bone Metastasis - Companies Involved in Therapeutics Development 21
Ablynx NV 21
Alethia Biotherapeutics Inc. 22
Amgen Inc. 23
Amura Holdings Ltd. 24
Bayer AG 25
ChemoCentryx, Inc. 26
Debiopharm International S.A. 27
Deciphera Pharmaceuticals, LLC 28
Digna Biotech, S.L. 29
Medivir AB 30
Merrion Pharmaceuticals Plc 31
Osteologix Holdings Plc. 32
Sigma-Tau S.p.A. 34
Bone Metastasis - Therapeutics Assessment 35
Priced at US $2000 for a single user PDF, a discount on this research report can be requested at http://www.rnrmarketresearch.com/contacts/discount?rname=356479 .
RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. (http://www.rnrmarketresearch.com/latest_reports .)